{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T15:11:58Z","timestamp":1779203518964,"version":"3.51.4"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T00:00:00Z","timestamp":1655251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T00:00:00Z","timestamp":1655251200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Heart Fail Rep"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose of Review\n<\/jats:title>\n                <jats:p>Heart failure (HF), in conjunction with common comorbidities such as chronic kidney disease and diabetes and medical therapies such as RAASi, predisposes to hyperkalaemia which may lead to hospitalisation and death. This paper aims to review the most current evidence surrounding the risks and management of hyperkalaemia in HF, with particular focus on recent research into RAASi including novel selective mineralocorticoid receptor blockers and novel potassium binders.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Recent Findings<\/jats:title>\n                <jats:p>The most recent evidence shows that even moderate hyperkalaemia may predispose to adverse outcomes such as hospitalisation and death. Furthermore, it may prevent patients from receiving optimal medical therapy for HF by reducing prescription of RAASi therapy. Novel potassium binders such as sodium zirconium cyclosilicate (SZC) and patiromer present potential options to reduce and prevent hyperkalaemia as well as maintain optimal RAASi dosing in HF.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Summary<\/jats:title>\n                <jats:p>Management of hyperkalaemia in HF has advanced in recent years. New therapies such as SZC and patiromer are contributing to the management of acute hyperkalaemia and also access to life-saving RAASi therapies by tackling and preventing hyperkalaemia in the community.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11897-022-00552-3","type":"journal-article","created":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T07:02:58Z","timestamp":1655276578000},"page":"191-199","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Hyperkalaemia in Heart Failure: Consequences for Outcome and Sequencing of Therapy"],"prefix":"10.1007","volume":"19","author":[{"given":"Daniel","family":"Murphy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6863-2325","authenticated-orcid":false,"given":"Debasish","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,15]]},"reference":[{"issue":"25","key":"552_CR1","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","volume":"76","author":"GA Roth","year":"2020","unstructured":"Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global burden of cardiovascular diseases and risk factors, 1990\u20132019. J Am Coll Cardiol. 2020;76(25):2982\u20133021.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"552_CR2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jchf.2018.10.003","volume":"7","author":"G Savarese","year":"2019","unstructured":"Savarese G, Xu H, Trevisan M, Dahlstr\u00f6m U, Rossignol P, Pitt B, et al. Incidence, predictors, and outcome associations of dyskalemia in heart failure with preserved, mid-range, and reduced ejection fraction. JACC Heart Fail. 2019;7(1):65\u201376.","journal-title":"JACC Heart Fail"},{"issue":"6","key":"552_CR3","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1038\/ki.2015.243","volume":"88","author":"RA Preston","year":"2015","unstructured":"Preston RA, Afshartous D, Rodco R, Alonso AB, Garg D. Evidence for a gastrointestinal\u2013renal kaliuretic signaling axis in humans. Kidney Int. 2015;88(6):1383\u201391.","journal-title":"Kidney Int"},{"key":"552_CR4","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105835","volume":"172","author":"GL Hundemer","year":"2021","unstructured":"Hundemer GL, Sood MM. Hyperkalemia with RAAS inhibition: mechanism, clinical significance, and management. Pharmacol Res. 2021;172: 105835.","journal-title":"Pharmacol Res"},{"key":"552_CR5","doi-asserted-by":"publisher","unstructured":"Thomsen RW, Nicolaisen SK, Hasvold P, Garcia\u2010Sanchez R, Pedersen L, Adelborg K, et al. Elevated potassium levels in patients with congestive heart failure: occurrence, risk factors, and clinical outcomes: a Danish population\u2010based cohort study. J Am Heart Assoc [Internet]. 2018 Jun 5 [cited 2021 Oct 19];7(11). Available from: https:\/\/www.ahajournals.org\/doi\/https:\/\/doi.org\/10.1161\/JAHA.118.008912.","DOI":"10.1161\/JAHA.118.008912"},{"key":"552_CR6","doi-asserted-by":"publisher","unstructured":"Palaka E, Grandy S, Darlington O, McEwan P, Doornewaard A. Associations between serum potassium and adverse clinical outcomes: a systematic literature review. Int J Clin Pract [Internet]. 2020 Jan [cited 2021 Oct 19];74(1). Available from: https:\/\/onlinelibrary.wiley.com\/doi\/https:\/\/doi.org\/10.1111\/ijcp.13421.","DOI":"10.1111\/ijcp.13421"},{"issue":"8","key":"552_CR7","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1002\/ejhf.1724","volume":"22","author":"P Rossignol","year":"2020","unstructured":"Rossignol P, Duarte K, Girerd N, Karoui M, McMurray JJV, Swedberg K, et al. Cardiovascular risk associated with serum potassium in the context of mineralocorticoid receptor antagonist use in patients with heart failure and left ventricular dysfunction. Eur J Heart Fail. 2020;22(8):1402\u201311.","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"552_CR8","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/ehjcvp\/pvv026","volume":"1","author":"ML Krogager","year":"2015","unstructured":"Krogager ML, Eggers-Kaas L, Aasbjerg K, Mortensen RN, K\u00f8ber L, Gislason G, et al. Short-term mortality risk of serum potassium levels in acute heart failure following myocardial infarction. Eur Heart J - Cardiovasc Pharmacother. 2015;1(4):245\u201351.","journal-title":"Eur Heart J - Cardiovasc Pharmacother"},{"issue":"12","key":"552_CR9","doi-asserted-by":"crossref","first-page":"499","DOI":"10.3390\/jcm7120499","volume":"7","author":"M Provenzano","year":"2018","unstructured":"Provenzano M, Minutolo R, Chiodini P, Bellizzi V, Nappi F, Russo D, et al. Competing-risk analysis of death and end stage kidney disease by hyperkalaemia status in non-dialysis chronic kidney disease patients receiving stable nephrology care. J Clin Med. 2018;7(12):499.","journal-title":"J Clin Med"},{"issue":"36","key":"552_CR10","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599\u2013726.","journal-title":"Eur Heart J"},{"issue":"11","key":"552_CR11","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.jchf.2019.07.010","volume":"7","author":"JC Beusekamp","year":"2019","unstructured":"Beusekamp JC, Tromp J, Cleland JGF, Givertz MM, Metra M, O\u2019Connor CM, et al. Hyperkalemia and treatment with RAAS inhibitors during acute heart failure hospitalizations and their association with mortality. JACC Heart Fail. 2019;7(11):970\u20139.","journal-title":"JACC Heart Fail"},{"issue":"5","key":"552_CR12","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1093\/ndt\/gfz263","volume":"36","author":"JB Wetmore","year":"2021","unstructured":"Wetmore JB, Yan H, Horne L, Peng Y, Gilbertson DT. Risk of hyperkalemia from renin\u2013angiotensin\u2013aldosterone system inhibitors and factors associated with treatment discontinuities in a real-world population. Nephrol Dial Transplant. 2021;36(5):826\u201339.","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"552_CR13","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/ehf2.12402","volume":"6","author":"C Linde","year":"2019","unstructured":"Linde C, Qin L, Bakhai A, Furuland H, Evans M, Ayoubkhani D, et al. Serum potassium and clinical outcomes in heart failure patients: results of risk calculations in 21 334 patients in the UK. ESC Heart Fail. 2019;6(2):280\u201390.","journal-title":"ESC Heart Fail"},{"issue":"6","key":"552_CR14","doi-asserted-by":"crossref","first-page":"e0218739","DOI":"10.1371\/journal.pone.0218739","volume":"14","author":"K Adelborg","year":"2019","unstructured":"Adelborg K, Nicolaisen SK, Hasvold P, Palaka E, Pedersen L, Thomsen RW. Predictors for repeated hyperkalemia and potassium trajectories in high-risk patients \u2014 a population-based cohort study Shearer G, editor. PLOS ONE. 2019;14(6):e0218739.","journal-title":"PLOS ONE."},{"issue":"11","key":"552_CR15","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJV McMurray","year":"2014","unstructured":"McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993\u20131004.","journal-title":"N Engl J Med"},{"issue":"17","key":"552_CR16","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","volume":"381","author":"SD Solomon","year":"2019","unstructured":"Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, et al. Angiotensin\u2013neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381(17):1609\u201320.","journal-title":"N Engl J Med"},{"issue":"6","key":"552_CR17","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJMoa1812851","volume":"380","author":"EJ Velazquez","year":"2019","unstructured":"Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, McCague K, et al. Angiotensin\u2013neprilysin inhibition in acute decompensated heart failure. N Engl J Med. 2019;380(6):539\u201348.","journal-title":"N Engl J Med"},{"issue":"1","key":"552_CR18","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","volume":"364","author":"F Zannad","year":"2011","unstructured":"Zannad F, McMurray JJV, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11\u201321.","journal-title":"N Engl J Med"},{"issue":"15","key":"552_CR19","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","volume":"370","author":"B Pitt","year":"2014","unstructured":"Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370(15):1383\u201392.","journal-title":"N Engl J Med"},{"issue":"16","key":"552_CR20","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1016\/j.jacc.2016.02.033","volume":"67","author":"F Beygui","year":"2016","unstructured":"Beygui F, Cayla G, Roule V, Roubille F, Delarche N, Silvain J, et al. Early aldosterone blockade in acute myocardial infarction. J Am Coll Cardiol. 2016;67(16):1917\u201327.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"552_CR21","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","volume":"325","author":"The SOLVD Investigators*","year":"1991","unstructured":"The SOLVD Investigators*. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325(5):293\u2013302.","journal-title":"N Engl J Med."},{"issue":"10","key":"552_CR22","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341(10):709\u201317.","journal-title":"N Engl J Med"},{"issue":"23","key":"552_CR23","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","volume":"345","author":"JN Cohn","year":"2001","unstructured":"Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345(23):1667\u201375.","journal-title":"N Engl J Med"},{"issue":"9386","key":"552_CR24","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","volume":"362","author":"JJV McMurray","year":"2003","unstructured":"McMurray JJV, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet Lond Engl. 2003;362(9386):767\u201371.","journal-title":"Lancet Lond Engl"},{"issue":"9386","key":"552_CR25","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","volume":"362","author":"CB Granger","year":"2003","unstructured":"Granger CB, McMurray JJV, Yusuf S, Held P, Michelson EL, Olofsson B, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet Lond Engl. 2003;362(9386):772\u20136.","journal-title":"Lancet Lond Engl"},{"issue":"17","key":"552_CR26","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1161\/01.CIR.0000146819.43235.A9","volume":"110","author":"JB Young","year":"2004","unstructured":"Young JB, Dunlap ME, Pfeffer MA, Probstfield JL, Cohen-Solal A, Dietz R, et al. Mortality and morbidity reduction with candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation. 2004;110(17):2618\u201326.","journal-title":"Circulation"},{"issue":"15","key":"552_CR27","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","volume":"370","author":"B Pitt","year":"2014","unstructured":"Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370(15):1383\u201392.","journal-title":"N Engl J Med"},{"issue":"17","key":"552_CR28","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","volume":"381","author":"SD Solomon","year":"2019","unstructured":"Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, et al. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. N Engl J Med. 2019;381(17):1609\u201320.","journal-title":"N Engl J Med"},{"issue":"6","key":"552_CR29","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJMoa1812851","volume":"380","author":"EJ Velazquez","year":"2019","unstructured":"Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, McCague K, et al. Angiotensin\u2013neprilysin inhibition in acute decompensated heart failure. N Engl J Med. 2019;380(6):539\u201348.","journal-title":"N Engl J Med"},{"issue":"23","key":"552_CR30","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219\u201329.","journal-title":"N Engl J Med"},{"key":"552_CR31","doi-asserted-by":"crossref","unstructured":"Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;NEJMoa2110956.","DOI":"10.1056\/NEJMoa2110956"},{"issue":"1","key":"552_CR32","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1681\/ASN.2021070942","volume":"33","author":"R Agarwal","year":"2022","unstructured":"Agarwal R, Joseph A, Anker SD, Filippatos G, Rossing P, Ruilope LM, et al. Hyperkalemia risk with finerenone: results from the FIDELIO-DKD trial. J Am Soc Nephrol. 2022;33(1):225\u201337.","journal-title":"J Am Soc Nephrol"},{"issue":"21","key":"552_CR33","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, K\u00f8ber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995\u20132008.","journal-title":"N Engl J Med"},{"key":"552_CR34","doi-asserted-by":"crossref","unstructured":"Voors AA, Angermann CE, Teerlink JR, Collins SP, Kosiborod M, Biegus J, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med. 2022","DOI":"10.1038\/s41591-021-01659-1"},{"issue":"36","key":"552_CR35","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599\u2013726.","journal-title":"Eur Heart J"},{"key":"552_CR36","unstructured":"National Institute for Health and Care Excellence. Dapagliflozin for treating chronic heart failure with reduced ejection fraction (TA679). 2021;25."},{"issue":"15","key":"552_CR37","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413\u201324.","journal-title":"N Engl J Med"},{"issue":"16","key":"552_CR38","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, B\u00f6hm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451\u201361.","journal-title":"N Engl J Med"},{"key":"552_CR39","doi-asserted-by":"crossref","unstructured":"Tomasoni D, Fonarow GC, Adamo M, Anker SD, Butler J, Coats AJS, et al. Sodium\u2013glucose co\u2010transporter 2 inhibitors as an early, first\u2010line therapy in patients with heart failure and reduced ejection fraction. Eur J Heart Fail. 2022;ejhf.2397.","DOI":"10.1002\/ejhf.2397"},{"issue":"8","key":"552_CR40","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1002\/ejhf.2286","volume":"23","author":"WG Herrington","year":"2021","unstructured":"Herrington WG, Savarese G, Haynes R, Marx N, Mellbin L, Lund LH, et al. Cardiac, renal, and metabolic effects of sodium-glucose co-transporter 2 inhibitors: a position paper from the European Society of Cardiology ad-hoc task force on sodium-glucose co-transporter 2 inhibitors. Eur J Heart Fail. 2021;23(8):1260\u201375.","journal-title":"Eur J Heart Fail"},{"issue":"11","key":"552_CR41","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","volume":"7","author":"BL Neuen","year":"2019","unstructured":"Neuen BL, Young T, Heerspink HJL, Neal B, Perkovic V, Billot L, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2019;7(11):845\u201354.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"552_CR42","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.jacc.2021.01.044","volume":"77","author":"JP Ferreira","year":"2021","unstructured":"Ferreira JP, Zannad F, Pocock SJ, Anker SD, Butler J, Filippatos G, et al. Interplay of mineralocorticoid receptor antagonists and empagliflozin in heart failure: EMPEROR-Reduced. J Am Coll Cardiol. 2021;77(11):1397\u2013407.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"552_CR43","first-page":"125","volume":"7","author":"Y Yavin","year":"2016","unstructured":"Yavin Y, Mansfield TA, Ptaszynska A, Johnsson K, Parikh S, Johnsson E. Effect of the SGLT2 inhibitor dapagliflozin on potassium levels in patients with type 2 diabetes mellitus: a pooled analysis. Diabetes Ther Res Treat Educ Diabetes Relat Disord. 2016;7(1):125\u201337.","journal-title":"Diabetes Ther Res Treat Educ Diabetes Relat Disord"},{"issue":"2","key":"552_CR44","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021;384(2):117\u201328.","journal-title":"N Engl J Med"},{"issue":"48","key":"552_CR45","doi-asserted-by":"crossref","first-page":"4891","DOI":"10.1093\/eurheartj\/ehab497","volume":"42","author":"BL Neuen","year":"2021","unstructured":"Neuen BL, Oshima M, Perkovic V, Agarwal R, Arnott C, Bakris G, et al. Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial. Eur Heart J. 2021;42(48):4891\u2013901.","journal-title":"Eur Heart J"},{"issue":"20","key":"552_CR46","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","volume":"382","author":"PW Armstrong","year":"2020","unstructured":"Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, et al. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med. 2020;382(20):1883\u201393.","journal-title":"N Engl J Med"},{"issue":"2","key":"552_CR47","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1056\/NEJMoa2025797","volume":"384","author":"JR Teerlink","year":"2021","unstructured":"Teerlink JR, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon SD, et al. Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure. N Engl J Med. 2021;384(2):105\u201316.","journal-title":"N Engl J Med"},{"issue":"1","key":"552_CR48","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/jamacardio.2021.4027","volume":"7","author":"GM Felker","year":"2022","unstructured":"Felker GM, Solomon SD, Claggett B, Diaz R, McMurray JJV, Metra M, et al. Assessment of omecamtiv mecarbil for the treatment of patients with severe heart failure: a post hoc analysis of data from the GALACTIC-HF randomized clinical trial. JAMA Cardiol. 2022;7(1):26.","journal-title":"JAMA Cardiol"},{"key":"552_CR49","unstructured":"National Institute for Health and Care Excellence. Patiromer for treating hyperkalaemia (TA623). 2020."},{"key":"552_CR50","unstructured":"National Institute for Health and Care Excellence. Sodium zirconium cyclosilicate for treating hyperkalaemia (TA599). 2019."},{"issue":"7","key":"552_CR51","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1093\/eurheartj\/ehq502","volume":"32","author":"B Pitt","year":"2011","unstructured":"Pitt B, Anker SD, Bushinsky DA, Kitzman DW, Zannad F, Huang I-Z, et al. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J. 2011;32(7):820\u20138.","journal-title":"Eur Heart J"},{"issue":"3","key":"552_CR52","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1410853","volume":"372","author":"MR Weir","year":"2015","unstructured":"Weir MR, Bakris GL, Bushinsky DA, Mayo MR, Garza D, Stasiv Y, et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med. 2015;372(3):211\u201321.","journal-title":"N Engl J Med"},{"issue":"10208","key":"552_CR53","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(19)32135-X","volume":"394","author":"R Agarwal","year":"2019","unstructured":"Agarwal R, Rossignol P, Romero A, Garza D, Mayo MR, Warren S, et al. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial. The Lancet. 2019;394(10208):1540\u201350.","journal-title":"The Lancet"},{"key":"552_CR54","unstructured":"Joint Formulary Committee. Patiromer calcium. In: British National Formulary [Internet]. London: British Medical Association and Royal Pharmaceutical Society of Great Britain; 2021 [cited 2022 Jan 6]. Available from: https:\/\/bnf.nice.org.uk\/drug\/patiromer-calcium.html."},{"issue":"1","key":"552_CR55","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/acem.13868","volume":"27","author":"Z Rafique","year":"2020","unstructured":"Rafique Z, Liu M, Staggers KA, Minard CG, Peacock WF. Patiromer for treatment of hyperkalemia in the emergency department: a pilot study. Baumann BM, editor. Acad Emerg Med. 2020;27(1):54\u201360.","journal-title":"Acad Emerg Med."},{"key":"552_CR56","doi-asserted-by":"crossref","DOI":"10.1016\/j.curtheres.2021.100635","volume":"95","author":"DB Shrestha","year":"2021","unstructured":"Shrestha DB, Budhathoki P, Sedhai YR, Baniya R, Cable CA, Kashiouris MG, et al. Patiromer and sodium zirconium cyclosilicate in treatment of hyperkalemia: a systematic review and meta-analysis. Curr Ther Res. 2021;95: 100635.","journal-title":"Curr Ther Res"},{"issue":"2","key":"552_CR57","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/ki.2014.382","volume":"88","author":"SR Ash","year":"2015","unstructured":"Ash SR, Singh B, Lavin PT, Stavros F, Rasmussen HS. A phase 2 study on the treatment of hyperkalemia in patients with chronic kidney disease suggests that the selective potassium trap, ZS-9, is safe and efficient. Kidney Int. 2015;88(2):404\u201311.","journal-title":"Kidney Int"},{"issue":"3","key":"552_CR58","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1411487","volume":"372","author":"DK Packham","year":"2015","unstructured":"Packham DK, Rasmussen HS, Lavin PT, El-Shahawy MA, Roger SD, Block G, et al. Sodium zirconium cyclosilicate in hyperkalemia. N Engl J Med. 2015;372(3):222\u201331.","journal-title":"N Engl J Med"},{"issue":"21","key":"552_CR59","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1001\/jama.2014.15688","volume":"312","author":"M Kosiborod","year":"2014","unstructured":"Kosiborod M, Rasmussen HS, Lavin P, Qunibi WY, Spinowitz B, Packham D, et al. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial. JAMA. 2014;312(21):2223\u201333.","journal-title":"JAMA"},{"issue":"1","key":"552_CR60","first-page":"54","volume":"7","author":"F Zannad","year":"2020","unstructured":"Zannad F, Hsu B-G, Maeda Y, Shin SK, Vishneva EM, Rensfeldt M, et al. Efficacy and safety of sodium zirconium cyclosilicate for hyperkalaemia: the randomized, placebo-controlled HARMONIZE-Global study. ESC Heart Fail. 2020;7(1):54\u201364.","journal-title":"ESC Heart Fail"},{"issue":"10","key":"552_CR61","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/ejhf.300","volume":"17","author":"SD Anker","year":"2015","unstructured":"Anker SD, Kosiborod M, Zannad F, Pi\u00f1a IL, McCullough PA, Filippatos G, et al. Maintenance of serum potassium with sodium zirconium cyclosilicate ( ZS -9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial. Eur J Heart Fail. 2015;17(10):1050\u20136.","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"552_CR62","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/acem.13954","volume":"27","author":"WF Peacock","year":"2020","unstructured":"Peacock WF, Rafique Z, Vishnevskiy K, Michelson E, Vishneva E, Zvereva T, et al. Emergency potassium normalization treatment including sodium zirconium cyclosilicate: a phase II, randomized, double-blind, placebo-controlled study (ENERGIZE). Heard KJ, editor. Acad Emerg Med. 2020;27(6):475\u201386.","journal-title":"Acad Emerg Med."},{"key":"552_CR63","unstructured":"Alfonzo A, Harrison A, Baines R, Chu A, Mann S, MacRury M. Clinical practice guidelines: treatment of acute hyperkalaemia in adults [Internet]. The Renal Association; 2020 p. 161. Available from: https:\/\/ukkidney.org\/sites\/renal.org\/files\/RENAL%20ASSOCIATION%20HYPERKALAEMIA%20GUIDELINE%202020.pdf"},{"issue":"1","key":"552_CR64","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ekir.2017.10.001","volume":"3","author":"JG Abuelo","year":"2018","unstructured":"Abuelo JG. Treatment of severe hyperkalemia: confronting 4 fallacies. Kidney Int Rep. 2018;3(1):47\u201355.","journal-title":"Kidney Int Rep"},{"key":"552_CR65","unstructured":"AstraZeneca. Lokelma (sodium zirconium cyclosilicate) for oral suspension: summary of product characteristics. [Internet]. 2018 [cited 2022 Jan 19]. Available from: https:\/\/www.ema.europa.eu\/"},{"issue":"12","key":"552_CR66","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0114686","volume":"9","author":"F Stavros","year":"2014","unstructured":"Stavros F, Yang A, Leon A, Nuttall M, Rasmussen HS. Characterization of structure and function of ZS-9, a K+ selective ion trap. PLoS ONE. 2014;9(12): e114686.","journal-title":"PLoS ONE"},{"issue":"27","key":"552_CR67","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa2110730","volume":"385","author":"R Agarwal","year":"2021","unstructured":"Agarwal R, Sinha AD, Cramer AE, Balmes-Fenwick M, Dickinson JH, Ouyang F, et al. Chlorthalidone for hypertension in advanced chronic kidney disease. N Engl J Med. 2021;385(27):2507\u201319.","journal-title":"N Engl J Med"},{"issue":"1","key":"552_CR68","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1186\/s12882-021-02439-2","volume":"22","author":"D Murphy","year":"2021","unstructured":"Murphy D, Ster IC, Kaski J-C, Anderson L, Banerjee D. The LIFT trial: study protocol for a double-blind, randomised, placebo-controlled trial of K+-binder Lokelma for maximisation of RAAS inhibition in CKD patients with heart failure. BMC Nephrol. 2021;22(1):254.","journal-title":"BMC Nephrol"}],"container-title":["Current Heart Failure Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-022-00552-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11897-022-00552-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-022-00552-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T14:36:50Z","timestamp":1659364610000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11897-022-00552-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,15]]},"references-count":68,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["552"],"URL":"https:\/\/doi.org\/10.1007\/s11897-022-00552-3","relation":{},"ISSN":["1546-9530","1546-9549"],"issn-type":[{"value":"1546-9530","type":"print"},{"value":"1546-9549","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,15]]},"assertion":[{"value":"18 April 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"DB has received grants from Kidney Research UK and AstraZeneca and speaker fees from Vifor Pharma. DM has received funding from \u201cSabita Research Fund\u201d through St George\u2019s Hospital Charity.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}